Email this article Intermittiruyushchaya gormonal'naya terapiya pri rake predstatel'noy zhelezy s posledovatel'nym naznacheniem lyuteiniziruyushchego gormona-rilizing-gormona i antiandrogenov
- Authors: Rusakov IG1, Sokov DG1
-
Affiliations:
- Issue: Vol 15, No 4 (2010)
- Pages: 33-37
- Section: Articles
- URL: https://rjonco.com/1028-9984/article/view/39819
- DOI: https://doi.org/10.17816/onco39819
- ID: 39819
Cite item
Full Text
Abstract
The authors analyze the results of palliative treatment in 51 patients with prostate cancer (PC) who received various regimens of hormone therapy. The follow-up time was 15.5 months.
A control group consisted of 25 patients with generalized (n = 14) and locally advanced (n = 11) PC. Of them, 14 patients took luteinizing hormone-releasing hormone (LHRH) agonists in a continuous regimen and 11 patients underwent bilateral orchiectomy after sensitivity evaluation via presumptive therapy with LHRH agonists within 2 months. In a study group, 14 patients received a LHRH agonist (zoladex) as a subcutaneous injection at a 28-day interval for 3 months. Then the therapy was discontinued and the oncomarker was monitored every month. The therapy was individually resumed if there was a considerable rise in prostate-specific antigen (PSA) or there were clinical symptoms.
Twelve patients had monotherapy with bicalutamide (casodex) 150 mg after an initial course of LHRH agonists (3 months). When the minimal PSA level was achieved, the drug was discontinued. When the PSA level was increased by more than 4 ng/ml, bicalutamide was given in a dose of 150 mg.
The study has demonstrated that intermittent hormone therapy considerably and significantly improves the quality of life in patients with PC versus those with continuous androgenic deprivation (a control group).
A control group consisted of 25 patients with generalized (n = 14) and locally advanced (n = 11) PC. Of them, 14 patients took luteinizing hormone-releasing hormone (LHRH) agonists in a continuous regimen and 11 patients underwent bilateral orchiectomy after sensitivity evaluation via presumptive therapy with LHRH agonists within 2 months. In a study group, 14 patients received a LHRH agonist (zoladex) as a subcutaneous injection at a 28-day interval for 3 months. Then the therapy was discontinued and the oncomarker was monitored every month. The therapy was individually resumed if there was a considerable rise in prostate-specific antigen (PSA) or there were clinical symptoms.
Twelve patients had monotherapy with bicalutamide (casodex) 150 mg after an initial course of LHRH agonists (3 months). When the minimal PSA level was achieved, the drug was discontinued. When the PSA level was increased by more than 4 ng/ml, bicalutamide was given in a dose of 150 mg.
The study has demonstrated that intermittent hormone therapy considerably and significantly improves the quality of life in patients with PC versus those with continuous androgenic deprivation (a control group).
Keywords
References
- Алексеев Б. Я., Нюшко К. М. // Онкоурология. - М., 2009. - С. 7.
- Алфимов А. Е., Сивков А. В. // Материалы Всероссийской науч.-практ. конф. "Современные возможности и новые направления в диагностике и лечении рака почки, мочевого пузыря, предстательной железы. - Уфа, 2001. - С. 24.
- Амосов Ф. Р. // Материалы Всероссийской науч.-практ. конф. "Современные возможности и новые направления в диагностике и лечении рака почки, мочевого пузыря, предстательной железы. - Уфа, 2001. - С. 28.
- Бухаркин Б. В. Современные методы лечения местно-распространенного и диссеминированного рака предстательной железы: Дис. ... д-ра мед. наук. - М., 1996.
- Злокачественные новообразования в России в 2007 году (заболеваемость и смертность) / Под ред. В. И. Чиссова и др. - М., 2008. - С. 98.
- Карякин О. Б. // Материалы 3-й Всероссийской науч. конф. с участием стран СНГ "Актуальные вопросы лечения онкоурологических заболеваний". - М., 1999. - С. 52-54.
- Лопаткин Н. А., Поповкин Н. Н., Зиборова И. В. и др. // Материалы пленума правления Российского общества урологов. - Омск, 2003. - С. 27-30.
- Мазо Е. Б. // Материалы пленума правления Российского общества урологов. - Омск, 2003. - С. 181-182.
- Матвеев Б. П., Бухаркин Б. В., Матвеев В. Б. Рак предстательной железы. - М., 2001.
- Матвеев Б. П. // Тезисы докл. симпозиума "Современные подходы к лечению онкоурологических заболеваний". - М. - С. 5-7.
- Молчанов О. Е., Тимофеев С. А. Метод оценки эффективности интермиттирующей гормональной терапии рака предстательной железы // Материалы X Всероссийского съезда урологов. - М., 2002. - С. 458-459.
- Русаков И. Г. // Материалы конф. "Онкологическая урология: от научных исследований к клинической практике (современные возможности диагностики и лечения опухолей предстательной железы, мочевого пузыря и почки)". - М., 2004. - С. 24-28.
- Состояние онкологической помощи населению России в 2007 году / Под ред. В. И. Чиссова и др. - М., 2008. - С. 104.
- Aus G., Abbou C., Bolla M. et al. Guidelines on prostate cancer. - 2008.
- Boccon-Gibod L., Bertaccini A., Bono A. V. et al. // Int. J. Clin. Pract. - 2003. - Vol. 57, N 3. - P. 187-194.
- Braga-Basaria M., Dobs A. S., Muller D. S. et al. // J. Clin. Oncol. - 2006. - Vol. 24. - P. 3979-3983.
- Bruchovsky N., Klotz L. H., Crook J. M. et al. Intermittent endocrine therapy for prostate cancer // Renal, bladder and prostate cancer / Eds K. H. Kurth et al. - London, 1998. - P. 173-182.
- Charing C. R., Rundle J. S. Flushing: Long term side-effect of orchidectomy in the treatment of carcinoma of the prostate // J. Urol. (Baltimore). - 1988. - Vol. 139. - P. 478A.
- Daneshgari F., Crawford E. D. Endocrine therapy of advanced carcinoma of the prostate // Cancer. - 1993. - Vol. 71. - P. 1089-1097.
- Daniell H. W. Osteoporosis after orchiectomy for prostate cancer // J. Urol. (Baltimore). - 1997. - Vol. 157. - P. 439-444.
- Gelave M. E., Hsieh S. T., Wu H. C. et al. Serum prostate specific antigen levels in mice bearing human prostate LNCap tumors are determined by tumor volume and endocrine and growth factors // Cancer Res. - 1992. - Vol. 52. - P. 1598-1605.
- Las Farrugia D., Ausell W., Singh M. et al. Stilboestrol plus adrenal suppression as salvage treatment with luteinizing hormone-realising hormone analogues and orchidectomy // Br. J. Urol. Int. - 2000. - Vol. 85. - P. 1069-1073.
- Robinson M. R., Smith P. H., Richards B. et al. The final analysis of the EORTC Genito-Urinary tract cancer Co-Operative Group phase III clinical trial (protocol 30805) comparing orchidectomy, orchidectomy plus cyproterone acetate and low dose stilboestrol in the management of metastatic carcinoma of the prostate // Eur. Urol. - 1995. - Vol. 28. - P. 273-283.
- Tyrrell C. J., Kaisary A. V., Iversen P. et al. A randomised comparison of "Casodex" (Bicalutamide) 150 mg monotherapy versus castration in the treatment of advanced prostatic cancer. Evidence Report (Technology Assessment N 4 AHCPR, Publication N 99-E0012. - Rockville, 1999.
Supplementary files
